878805-70-0

Basic information

• Product Name: Carbamic acid, [(1S)-1-(4-ethenylphenyl)ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 878805-70-0
• Molecular Formula: C15H21NO2
• Molecular Weight: 247.337
• Mol File: 878805-70-0.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(1S)-1-(4-ethenylphenyl)ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-1-(4-ethenylphenyl)ethyl]-, 1,1-dimethylethyl ester(878805-70-0)
• EPA Substance Registry System: Carbamic acid, [(1S)-1-(4-ethenylphenyl)ethyl]-, 1,1-dimethylethyl ester(878805-70-0)

Safety Data

• Hazardous Substances Data: 878805-70-0(Hazardous Substances Data)

Upstream product

• 847728-89-6 (S)-tert-butyl (1-(4-bromophenyl)ethyl)carbamate 
• 1037252-32-6 [(S)-1-(4-formyl-phenyl)ethyl]carbamic acid tertbutyl ester 
• 1779-49-3 Methyltriphenylphosphonium bromide 

Downstream Products

• 19303-08-3 (1S)-1-(4-vinylphenyl)ethanamine 
• 1037251-78-7 tert-butyl ((1S)-1-{4-[(1S)-1,2-dihydroxyethyl]phenyl}ethyl)carbamate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS

The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm, endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS

The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a halogen atom, a lower

NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.